Go To Global Site
Welcome to UCB in the United States

Dec

16

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Oct

17

Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab

• The Phase 3 BE VIVID study evaluating the efficacy and safety of bimekizumab in adults with moderate-to-severe chronic plaque psoriasis met all primary and ranked secondary endpointsi